Coal mining firm TerraCom has taken its bid to shield a PricewaterhouseCoopers report from ASIC to the Full Court, appealing a judgment which found the regulator could view the report because of public statements made by the company.
A judge has approved a bid by group members to discontinue a class action alleging pharmacy giant Priceline exercised an “overly prescriptive level of control” on franchisees which limited their profitability, saying it was unlikely to succeed with a litigation funder.
Telstra has denied that it is liable to compensate a Queensland barrister who lost his phone numbers in an NBN transfer, arguing that it was the silk’s decision to terminate his contract with the company.
Toyota could owe close to $2 billion in compensation to 260,000 car owners after a judge found that diesel filters installed in its Hilux, Fortuner and Prado models were defective and that the cars were sold for more than they were worth.
The trustee of Mayfair Group’s collapsed IPO Wealth Fund has reached an in-principle settlement in a class action alleging it misled investors, who lost $86 million when the fund was wound up.
A judge has hit Westpac with a $1.5 million penalty for misleading 141 customers into believing they had purchased add-on insurance.
Insurance Australia Group is investigating the underwriter behind an allegedly unauthorised trade credit policy issued to Greensill Capital, according to a defence by the insurer in a $43 million case brought by a Credit Suisse supply chain fund left heavily exposed after Greensill’s collapse.
Law firm Russells has won a bid for further security against former clients in a negligence case over its handling of a shareholder suit against iron ore miner Macarthur Minerals.
The maker of the popular Invisalign dental aligners may soon face a cross-claim from competitor SmileDirectClub, which it sued for allegedly misleading consumers about the cost and efficacy of its direct-to-consumer teeth alignment kits.
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.